Primary Responsibilities:
- Fully accountable for building and overseeing the nonclinical/translational strategy for company programs. Responsible for the design and execution of nonclinical (safety/toxicology, bioanalysis, PK/PD/ADME) plans to efficiently advance molecules at all stages of drug development; including non-GLP and GLP-compliant studies
- Build the nonclinical development function with the requisite scientific, safety/toxicology, PK/ADME and regulatory expertise
- Guide early clinical dosing strategy by integrating relevant nonclinical data
- Work in close collaboration with the Lycia Leadership team and project team leads, contract research organizations (CROs) and external consultants to advance multiple drug candidates into and through clinical development
- Serve as a departmental representative and/or project leader for pipeline programs
- May also support clinical pharmacology activities for development programs
- Ensures timely, clear and accurate communication and interpretation of study results to facilitate productive discussion and effective decision making
- Coordinate and contribute to the preparation of documents required for regulatory meetings and submissions
- May serve as the company representative or subject matter expert in meetings with external stakeholders (business partners/collaborators, vendors, investigators, regulatory agencies)
- Maintain a current understanding of drug development and translational science literature and methodology relevant for the advancement of drug discovery projects
- Member of scientific leadership team that will work effectively and collaboratively with other departments and cross-functional teams, and contribute to building a positive, team-oriented culture
Qualifications:
- Requires a Ph.D. in toxicology, pharmacology or other pharmaceutical or biological science
- 10+ years of industry experience beyond postdoctoral work in drug development and 5+ years of successful functional area management/ leadership
- Experience and accomplishment in progressing large molecule, small molecule, and antibody drug conjugate candidates from research through development (resulting in successful INDs and/or BLA/NDA/MAAs).
- Strong knowledge of nonclinical drug development, FDA and ICH guidelines and GLP/GMP regulations
- Experience in designing, conducting and interpreting nonclinical pharmacology, PK/PD/ADME and toxicology studies
- Experience in working with external CROs with timely and successful delivery of studies and well-written deliverables; experience collaborating and managing consultants in various areas of nonclinical sciences
- Understanding of CMC, QA, clinical and regulatory stages to effectively support nonclinical and project activities throughout development
- Experience in writing nonclinical sections of regulatory documents and direct interaction with the FDA/health authorities
- Demonstrated ability to build and lead high functioning, collaborative and driven teams (both internal and external), and mentoring direct reports and/or junior cross-functional colleagues as applicable
- Excellent strategic thinking, problem-solving and analytical skills
- Excellent written and verbal communication skills
- Ability to build collaborative relationships both internally and externally
- Flexible and dynamic interpersonal approach, entrepreneurial by nature, a collaborative team player who works well with physicians, scientists, managers, peers, and staff
- Ability to manage in a consensus environment through teamwork, trust and shared expectations, influencing strategic direction of complex global regulatory issues, solicit information, listen well, persuade others, make important decisions and shape outcomes.
Skills Required
- Ph.D. in toxicology, pharmacology, or other pharmaceutical or biological science
- 10+ years of industry experience in drug development
- 5+ years of successful functional area management/leadership
- Experience progressing large and small molecule candidates to INDs and BLAs
- Strong knowledge of FDA and ICH guidelines
- Experience in designing and conducting toxicology studies
- Experience writing regulatory documents and direct interaction with FDA
- Ability to build and lead high functioning teams
What We Do
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.






